Platelets as Pathophysiological Drivers of Thrombo-Inflammation and Immune Response
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 52763
Special Issue Editors
Interests: thrombosis; thrombo-inflammation; free radical biology; platelets; neutrophils; coronary artery disease; anti-platelet drug targets
Interests: thrombus formation; platelet biology; antithrombotic medication
Special Issue Information
Dear Colleagues,
Platelets are commendably versatile cells in circulation that not only perform the vital physiological processes of thrombosis-haemostasis, but actively mount inflammatory response in coordination with immune cells. Thrombosis and inflammation go hand-in-hand, whereby each can potentially act as a causative drive or the consequence. Inflammatory interaction of platelets with vascular (e.g. endothelial, smooth muscle cells) and circulatory cells (e.g. monocytes, neutrophils) sets the scene for cardio/cerebrovascular disease, silently leading to thrombo-ischemic adversities like acute myocardial infarction or acute ischemic stroke. Equipped with an array of TLRs, platelets also act as sentinel cells detecting bacterial or viral entry. However, exaggerated inflammatory response to pathogenic intrusion may turn out to be deleterious, as they disrupt physiological haemostasis, and dispose to pathological thrombosis. Both dysregulated coagulation and thrombotic complications have emerged as decisive factors influencing mortality associated with COVID-19 (SARS-CoV-2). Likewise, platelet functions are intricately affected by other viral (e.g. dengue, influenza, HIV-1), bacterial (e.g. E.coli; S. aureus) parasitic (e.g. malaria) infections and sepsis. Therefore, evaluating the molecular drivers of platelet-immune interaction is essential to overcome critical unforeseen challenges as recently encountered during the COVID-19 pandemic. Moreover, platelets themselves are subject to autoimmune or alloimmune challenges owing to inherited or acquired immune pathologies. These not only affect platelet count and turnover (e.g. ImmuneThrombocytoPenia-ITP) but also their functional attributes resulting in life threatening consequences (e.g. Heparin Induced Thrombocytopenia-HIT).
Considering the perplexity of platelet-immune cell interaction, investigations revealing molecular insights and implementing novel therapeutic strategies tailoring this thrombosis-inflammation interface, are undeniably the need of the hour. Ongoing preclinical and clinical studies are pursuing efficacious drug targets and testing novel therapeutics against atherosclerosis, cardio/cerebrovascular disease, deep vein thrombosis, pulmonary embolism, ITP, HIT-associated thrombosis. This ‘Special Issue’ aims to provide an overview and a translational perspective on the multifaceted aspects of thrombo-inflammation. This will not only reveal prospects to exploit therapeutically but also identify obstacles to be surmounted for thromboprophylaxis.
Scope for the special issue: Reviews, research articles, communications and technical notes on basic, preclinical, clinical studies exploring the pathophysiological role of platelets in immune homeostasis or during bacterial or viral infections; the thrombo-inflammatory attributes of platelets in Cardio/Cerebrovascular disease and in platelet associated inherited or acquired immune disorders.
Dr. Madhumita Chatterjee
Dr. Judith Cosemans
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Platelets
- thrombo-inflammation
- cardio/cerebrovascular disease
- infection
- immunity
- deep vein thrombosis
- pulmonary embolism
- ITP
- HIT
- sepsis
- anti-platelet therapy
- thromboprophylaxis.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.